- United States
- /
- Capital Markets
- /
- NYSE:WT
WisdomTree Second Quarter 2025 Earnings: EPS Misses Expectations
WisdomTree (NYSE:WT) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$112.6m (up 5.2% from 2Q 2024).
- Net income: US$24.8m (up 13% from 2Q 2024).
- Profit margin: 22% (up from 20% in 2Q 2024).
- EPS: US$0.17 (up from US$0.15 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
WisdomTree EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.2%.
Looking ahead, revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Capital Markets industry in the US.
Performance of the American Capital Markets industry.
The company's shares are up 5.8% from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for WisdomTree that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if WisdomTree might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:WT
WisdomTree
Through its subsidiaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager.
Reasonable growth potential with low risk.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets
Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Investment Analysis (May 2026)
Recently Updated Narratives

Baviera: A 40% ROCE Compounding Machine Trading at Distressed Multiples — Fair Value €88/share

Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point

A company I wrote off that quietly turned itself around
Popular Narratives

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Investment Analysis (May 2026)
